Combo Abi-olaparib better than sequential for BRCA1/2/ATM mutated #prostatecancer. Glad to see #BRCAaway published! Congrats #MahaHussain Neeraj Agarwal, MD, FASCO et al! PCF Science OncoAlert UroToday.com

#BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer. Maha Hussain Lurie Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber in this discussion, highlighting the journey from the inception of the trial to its execution. #WatchNow > bit.ly/43q4Z2g

#BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer. Maha Hussain Lurie Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber in this discussion, highlighting the journey from the inception of the trial to its execution. #WatchNow > bit.ly/43q4Z2g

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

#BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer. Maha Hussain Lurie Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber in this discussion, highlighting the journey from the inception of the trial to its execution. #WatchNow > bit.ly/43q4Z2g

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

#BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer. Maha Hussain Lurie Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber in this discussion, highlighting the journey from the inception of the trial to its execution. #WatchNow > bit.ly/43q4Z2g

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

#BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer. Maha Hussain Lurie Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber in this discussion, highlighting the journey from the inception of the trial to its execution. #WatchNow > bit.ly/43q4Z2g

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

March is #prostatecancer awareness month and what better time to hear about the latest in prostate cancer therapies? We have updates from the Phase II #BRCAAway trial, demonstrating the benefits of #combinationtherapy over #sequentialtherapy 🔦🎥 👉 vjoncology.com/video/k0etnzla…

Watch our expert discussions on notable trials presented at the ASCO GU Symposium around bladder, kidney and prostate cancer. ow.ly/8Bq650QAgnY #AMBASSADOR #BRCAAway #CheckMate914 #CONTACT2 #EV302 #GETUG-AFU18 #Keynote564 #SCNivolumab #GUCancer #MedOnc #OncEd #Oncology

#GU24 ASCO Highlights w/ Tian Zhang, MD, MHS - #CONTACT02 - #BRCAAWAY - #AMBASSADOR - #KN564 Full discussion: - Oncbrothers.com/guasco-2024 - targetedonc.com/data-dialogue-… - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter #gusm Targeted Oncology #MedEd #OncEd

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC. Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

#Combo Tx Best in #Metastatic #ProstateCancer with #HRR Mutations 👉tinyurl.com/yzrns4u4 MDedge Hematology & Oncology #BRCAAway #PFS

At ASCO #GU24, Dr. Maha Hussain presented results of the #BRCAAway trial, which examined the efficacy of #abiraterone, #olaparib, and a combination of the two in patients with mCRPC and HRRm. See which treatment resulted in longer PFS for patients: buff.ly/3vKEPdM

2. #BRCAAWAY: Ph II, n=165, mCRPC with BRCA 1/2 or ATM mutation, Abi vs Olaparib (sequential/crossover allowed) vs Abi/Olaparib: - Significant ⬆️ PFS with combo 39mos vs 8.4mos with Abi vs 14mos with Olaparib (PFS2 could be an important) - Combo (already approved) should be

Day 1 #GU24 ASCO Highlights #CommunityOncology 1. #CONTAC02: Atezo/Cabo mCRPC 2. #BRCAAWAY: PARPi in mCRPC 3. #EMBARK: High Risk biochemical recurrence #ProstateCancer cancer #OncEd #MedEd #OncTwitter #MedTwitter #gusm 1/4

According to the phase 2 #BRCAAway trial, #olaparib added to #abiraterone/#prednisone yielded longer PFS among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations. Learn more: hmpgloballearningnetwork.com/site/onc/confe… #medtwitter #onctwitter #GU24 #ASCOGU

#BRCAAway at ASCO #GU24 Maha Hussain shared insights into a phase 2 trial exploring abiraterone, olaparib, or their combo in #mCRPC pts with HRR mutations. 🩺🧬 Results show improved PFS, ORR, and PSA response rate with the combination! > bit.ly/492jFH7 Zach Klaassen